Coronary disease & ACS

Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction

Eur Heart J Cardiovasc PharmacotherPublished retrospectively analysed data from 500 consecutive patients

Authors' conclusion

The systematic introduction of a personalized, SES strategy for LLT in patients with acute MI led to greater achievement of LDL-C goal and lower risk of MACE at 1 year vs. the stepwise approach.

Study context

Population
Patients admitted for acute myocardial infarction (MI)consecutive patients hospitalized across three periods
Participants
500 patients
Comparison
Personalized, strike early and strong (SES) strategy for lipid-lowering therapy (LLT) vs. the stepwise approach
  • Period An = 198
  • Period Bn = 180
  • Period Cn = 122
Outcome
Achievement of the LDL-C goal during follow-up and 1-year incidence of MACE
Follow-up
During ; 1 year
Methodological detailsthree periods
  • Three periods

Main finding

As reported in the abstract

GroupLow-density lipoprotein cholesterol (LDL-C) goal achievementMajor adverse cardiovascular events (MACE)
Period A55%12%

Period A

Low-density lipoprotein cholesterol (LDL-C) goal achievement55%
Major adverse cardiovascular events (MACE)12%

Further findings

Lipid-lowering therapy at discharge

Higher use of potent statins, alone or in combination with ezetimibe, and of proprotein convertase subtilisin/kexin type 9 inhibitor inhibitors at discharge in Period C

MACE by LDL-C achievement

MACE rates were lowest in patients with early and sustained LDL-C <55 mg/dL and in those achieving both LDL-C <55 mg/dL and ≥50% LDL-C reduction

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. Published 24 January 2025. doi:10.1093/ehjcvp/pvaf004

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.